为您找到相关结果约500个

你是不是要搜索 期刊一项多中心、随机、双盲、安慰剂对照研究（ IVIG组：24，甲基强的松龙组：21），治疗期6个月 甲基强的松龙组(11/21，占52%)中止治疗的患者人数多于IVIg组（3/24,占12%） 在为期6个月的CIDP治疗中，IVIG组因治疗无效，副作用或反应不耐受而中止治疗的情况少于静脉输注甲基强的 点击跳转

IvIG with CIDP: A withdrawal attempt is possible

CIDP: IVIg dose finding for maintenance therapy

Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?

IVIG efficacy in CIDP patients is not associated with terminal complement inhibition

Switch from IVIg to SCIg in patients with CIDP: 6 months follow up study of quality of life

Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies

Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease

IVIG Refractory CIDP: Clinical Characteristics, Antibodies, and Response to Alternative Treatment

IVIG refractory CIDP: Clinical characteristics, antibodies and response to alternative treatment

CIDP: Analysis of Immunomarkers During COVID-19 mRNA-Vaccination and IVIg-Immunomodulation: An Exploratory

CAN NK CELLS HELP DISCRIMINATE IVIG TREATMENT RESPONSE IN PATIENTS WITH CIDP?

Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIg

IVIg responsive Chikungunya virus induced CIDP exacerbation in a patient with MGUS

NK cells as surrogate marker for predicting efficacy of IVIg in CIDP

为您找到相关结果约500个

共500条页码: 1/34页15条/页